Best Hospitals for Irritable Bowel Syndrome Treatment in Mumbai, India

Irritable Bowel Syndrome is classified as a disorder of gut-brain interaction (DGBI), formerly termed a functional gastrointestinal disorder, per the Rome IV diagnostic criteria established in 2016. The condition manifests as recurrent abdominal pain at least one day per week over the preceding three months, associated with two or more of the following: relation to defecation, change in stool frequency, or change in stool form. IBS is further subtyped into IBS-C (constipation-predominant), IBS-D (diarrhea-predominant), IBS-M (mixed bowel habits), and IBS-U (unclassified), each requiring a distinct therapeutic approach. The pathophysiology is multifactorial, involving visceral hypersensitivity mediated by sensitized afferent nociceptors in the enteric nervous system, dysregulation of the gut-brain axis (including serotonin signaling pathways — 90–95% of the body's serotonin is produced in the gut), intestinal microbiome dysbiosis, low-grade mucosal inflammation, altered intestinal permeability, and psychosocial comorbidities such as anxiety and depression.

• ELIGIBLE PATIENTS:
• Adults and adolescents (≥18 years for most pharmacological protocols; pediatric IBS managed separately) with a Rome IV–confirmed diagnosis of IBS-C, IBS-D, IBS-M, or IBS-U
• Patients who have failed first-line dietary and lifestyle modifications for ≥3–6 months without adequate symptom relief
• Patients with refractory IBS seeking second or third-line pharmacological or psychological interventions not accessible or affordable in their home country
• Patients requiring diagnostic exclusion of organic disease (IBD, colorectal cancer, celiac disease, microscopic colitis) prior to IBS management
• +20 more

IBS management is non-surgical and follows an evidence-based stepwise multimodal approach. Treatment is individualized based on IBS subtype (IBS-C, IBS-D, IBS-M), symptom severity (mild/moderate/severe per IBS-SSS), and the presence of comorbid psychological conditions.

STEP 1: Dietary & Lifestyle Interventions (first-line)

• Low-FODMAP Diet (Fermentable Oligosaccharides, Disaccharides, Monosaccharides, and Polyols): The most robustly evidence-based dietary intervention for IBS, with 50–86% of patients experiencing significant symptom reduction. Conducted in three structured phases: Elimination (2–6 weeks), Reintroduction (systematic FODMAP category re-challenge), and Personalization. Requires supervision by a trained dietitian with IBS expertise. Available in structured outpatient programs at GAF Healthcare partner centers.
• Soluble Fiber Supplementation: Psyllium husk (ispaghula) is recommended for IBS-C and IBS-M (evidence level: strong). Insoluble fiber (wheat bran) may worsen symptoms and is generally avoided.
• Gut-Healthy Lifestyle Counseling: Regular physical activity (150 min/week moderate intensity), sleep hygiene, and stress reduction strategies — all evidence-based adjuncts.
• Probiotics: Specific strains with evidence include Bifidobacterium infantis 35624, Lactobacillus plantarum 299v, and multi-strain preparations. Used as adjunct therapy; response is strain-specific and patient-variable.

STEP 2: Gut-directed Pharmacotherapy (second-line)

PHASE 1 — PRE-TRAVEL PREPARATION (2–4 weeks before departure):

• Step 1: Submit medical records to GAF Healthcare coordinator via secure portal (previous colonoscopy/endoscopy reports, blood work, imaging, current medications, and completed Rome IV symptom questionnaire and IBS-SSS)
• Step 2: GAF Healthcare medical team conducts virtual pre-consultation with the assigned gastroenterologist (India or UAE) to review records, confirm diagnosis, identify diagnostic gaps, and outline a personalized treatment plan
• Step 3: GAF Healthcare arranges e-Medical Visa (India) or UAE entry visa documentation, airport transfer scheduling, and hospital appointment coordination
• Step 4: Patient begins Low-FODMAP elimination phase under dietitian guidance (can be initiated remotely via GAF-partnered telehealth dietitian)

PHASE 2 — ARRIVAL & DIAGNOSTIC WORKUP (Days 1–4):